1 / 1

Summary

44% of PRAME is at TSS. p‹10 -20. The tumor antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters Nawel Mahrour 1* , A. Costessi 2* , E. Tijchon 2 , R. Stunnenberg 2 , M.A. Stoel 2 , P.W. Jansen 2 , D. Sela 1 ,

bono
Télécharger la présentation

Summary

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 44% of PRAME is at TSS p‹10-20 • The tumor antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters • Nawel Mahrour1*, A. Costessi2*, E. Tijchon2, R. Stunnenberg2, M.A. Stoel2, P.W. Jansen2, D. Sela1, • L. Florens1, S. Martin-Brown1, M.P. Washburn1,3, J.W. Conaway1,4, R.C. Conaway1,4 and H. Stunnenberg2 • Stowers Institute for Medical Research. Kansas City, MO 64110; 2. Dept. Molecular Biology, Radboud University, Nijmegen, The Netherlands; 3. Depts. of Pathology & Lab. Medicine and 4. Biochemistry & Mol Biology, University of Kansas Medical School, Kansas City, KS • * Equal contribution Substrate? Ub PRAME EloB E2 BC-Box Rbx1 EloC Cul2-Box Cul2 Introduction º PRAME (Preferentially expressed antigen in melanoma) is a human oncoprotein highly expressed in many tumors, but not present in normal tissues. º High PRAME expression is predictive of poor prognosis in melanoma, neuroblastoma and breast cancer. º Thus, PRAME may be a promising therapeutic target. º However, the molecular function(s) of PRAME are not yet understood. º Our aim is to elucidate PRAME’s role in oncogenesis at the molecular level. PRAME’s binding to Elongin BC depends on its BC-box PRAME’s binding to Cul2 + Rbx1 depends on its Cul2-box Multiple Sequence Alignment of PRAME with known Elongin BC- associating proteins predicts BC-box and Cul2-box motifs at PRAME’s N terminus BC-box Cul2-box Input TAG-IP BC-box mut BC-box mut Relative NSAfs WT WT TAG-PRAME Cul2 EloB PRAME pulls down all the components of a Cullin2-based ubiquitinligase RLVELAGQSL PRAME PRAME LPRELFPPL WT EloC WT LRR Tag RPVELFGQSL LRR Tag BC-box mutant AARELFPPL Cul2-box mutant BC-box Cul2-box BC-box Cul2-box PRAME complexes support poly-Ub chain formation in vitro PRAME assembles into a Cullin2-based ubiquitinligase - + + + + ATP + + + + - E1+E2 Flag-PRAME+B/C - + + + + His Cul2+Myc Rbx1 - + + + + Poly-Ub chains Flag-PRAME PRAME occupancy correlates positively with active histone marks and PolII and negatively with inactive marks Blot Flag/ Ub ChiP-Seq: PRAME is enriched at Transcription Start Sites (-87bp) PRAME is enriched at CCAAT motifs PRAME plays a role in gene activation • Summary • We applied protein-complex purification strategies (MudPIT) and showed that PRAME is the substrate recognition subunit of a Cullin2-based E3 ubiquitin ligase. • Genome-wide chromatin immunoprecipitation experiments reveal that PRAME is specifically enriched at transcriptionally active promoters that are also bound by NFY transcription factor. • Our data define a model for the biological function of PRAME, and support a role for the PRAME ubiquitin ligase complex in NFY-mediated transcriptional regulation, paving the road for understanding the functions of PRAME in normal cells and in human malignancies. PRAME colocalizes with transcription factors NFYA and NFYB

More Related